Tennessee Oncology Chattanooga

Clinical research site in Chattanooga, Tennessee · 1032 MCCALLIE AVE STE 200, CHATTANOOGA, TN 37403-2836 · (423) 708-6495

Part of Tennessee Oncology

As of July 2026, 11 paid clinical trials are recruiting at Tennessee Oncology Chattanooga in Chattanooga, Tennessee. Active studies at this site cover conditions such as Advanced Solid Tumors, B-Cell Non-Hodgkins Lymphoma and Colorectal Cancer (CRC). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Tennessee Oncology Chattanooga (11)

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

93 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

86 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

for Patients With Non-Small Cell Lung Cancer

31 locations incl. Beverly Hills

Sponsor: OSE Immunotherapeutics

Sex: All·Age: 18+

Code: NCT06472245·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

for Non-small Cell Lung Cancer (NSCLC)

21 locations incl. Orange

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05379985·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

More research sites in Chattanooga

Southeast Renal Research Institute (5 trials)
T C Thompson Children's Hospital (5 trials)
GSK Investigational Site (4 trials)
Tennessee Oncology, PLLC - Chattanooga Downtown (4 trials)
Tennessee Oncology, PLLC - Chattanooga Med Park II (4 trials)
Tennessee Oncology, PLLC - Chattanooga Memorial (4 trials)
Erlanger Health System (4 trials)
ClinSearch, LLC (3 trials)
Erlanger Health, Inc. (3 trials)
Tennessee Oncology (3 trials)

Explore more

Paid clinical trials in Chattanooga, TN · Tennessee clinical trials